Anisotropine Methylbromide API Manufacturers & Suppliers

Anisotropine methylbromide (CAS number 80-50-2) is a quaternary ammonium compound classified within the tropane alkaloid family. It was traditionally employed as an adjunct therapy in the management of peptic ulcer disease, used in combination with antacids or histamine H2-receptor antagonists to reduce gastric acid secretion and delay gastric emptying. However, its clinical use in this indication has largely been superseded by more effective pharmacologic agents.

Pharmacodynamically, anisotropine methylbromide exhibits a dose-dependent inhibitory effect on the motility and secretory activity of the gastrointestinal tract. It also decreases smooth muscle tone in the ureter and urinary bladder and exerts a mild relaxant effect on the bile ducts and gallbladder. At lower doses, the compound inhibits salivary and bronchial secretions, reduces sweating, impairs ocular accommodation, causes pupil dilation, and induces an increase in heart rate. Higher doses are necessary to achieve marked reduction in gastrointestinal and urinary tract motility and to inhibit gastric acid secretion.

The mechanism of action of anisotropine methylbromide involves antagonism at muscarinic acetylcholine receptors located on smooth muscles, cardiac tissues, sinoatrial and atrioventricular nodes, and exocrine glands. By inhibiting muscarinic receptor-mediated responses to acetylcholine released from postganglionic cholinergic nerves, it mitigates parasympathetic nervous system effects in target organs.

Absorption, distribution, metabolism, and excretion (ADME) parameters specific to anisotropine methylbromide are not extensively characterized in the literature, but as a quaternary ammonium compound, it generally exhibits limited central nervous system penetration due to ionization at physiological pH.

Safety considerations include potential anticholinergic side effects such as tachycardia, dry mouth, urinary retention, blurred vision, and reduced sweating. Overdose risks include exacerbation of these effects and potential cardiovascular complications. The compound’s quaternary ammonium structure reduces central anticholinergic adverse effects compared to tertiary analogs.

Notable product use contexts for anisotropine methylbromide have largely diminished given the availability of newer agents with improved efficacy and safety profiles. However, it remains approved in some markets for its historical indications.

From an API sourcing and quality perspective, procurement of anisotropine methylbromide should ensure compliance with pharmacopeial standards where applicable, with particular attention to purity, residual solvent limits, and confirmation of quaternary ammonium content. Due to its specialized use and reduced current demand, secure supply chains and validated analytical methods are critical for supporting pharmaceutical formulation and regulatory requirements.